Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents [note 3 and note 7] $ 15,546 $ 24,771
Grant receivable [note 4] 111 105
Prepaid expenses and other assets 1,325 2,454
Total current assets 16,982 27,330
Restricted cash and other assets [note 7 and note 8] 92 66
Right-of-use assets [note 12] 66 123
License agreement [note 5 and note 6] 1,197 1,418
Goodwill 1,034 1,034
Total assets 19,371 29,971
Current liabilities:    
Accounts payable 618 1,660
Accrued liabilities other 351 403
Contigent consideration [note 6 and note 7] 528
Accrued clinical liabilities 280 1,729
Accrued compensation 2,311 1,678
Current portion of long-term obligations [note 12] 63 58
Convertible debt [note 7 and note 9] 16,662 16,071
Total current liabilities 20,813 21,599
Long-term obligations [note 12] 6 69
Total liabilities 20,819 21,668
Commitments and contingencies [note 12]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 21,165,760 and 17,897,029 issued and outstanding at December 31, 2023 and December 31, 2022, respectively. 90 87
Additional paid-in capital 164,209 144,148
Accumulated deficit (165,751) (135,936)
Accumulated other comprehensive income 4 4
Total stockholders' equity (1,448) 8,303
Total liabilities and stockholders' equity 19,371 29,971
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value